Hikma v. Amarin — Supreme Court Protects Skinny-Label Generics from Induced Infringement Claims

Background

Amarin sells Vascepa, a prescription drug whose active ingredient is icosapent ethyl. The FDA approved Vascepa in 2012 for severe hypertriglyceridemia (the “SH indication”) and again in 2019 for reducing cardiovascular risk in hypertriglyceridemia patients already taking statins (the “CV indication”). Amarin obtained two method-of-use patents covering the CV indication — U.S. Patent Nos. 9,700,537 and 10,568,861.

Hikma filed an abbreviated new drug application (ANDA) for generic icosapent ethyl in 2016 under a paragraph IV certification challenging Amarin’s SH-indication patents. In 2019, while Hikma’s ANDA was still pending, the FDA approved Vascepa for the CV indication and Amarin obtained its CV-indication patents. A district court then invalidated Amarin’s SH-indication patents. Hikma responded by supplementing its ANDA with a section viii statement and a proposed “skinny label” — a Hatch-Waxman mechanism that carves the still-patented CV uses out of the generic’s labeling. The FDA approved Hikma’s skinny-label generic in 2020 with an “AB” therapeutic-equivalence rating.

Amarin sued in the District of Delaware for induced infringement of the CV-indication patents under 35 U.S.C. § 271(b). It pointed to the totality of four categories of Hikma statements: (1) the skinny label itself, which omitted Vascepa’s “CV Limitation of Use” and retained information about a clinical study involving statin patients; (2) the patient information leaflet, which warned about side effects in people with cardiovascular disease and noted that medicines are sometimes prescribed for off-label purposes; (3) Hikma’s website, which described the therapeutic category as “hypertriglyceridemia” and listed the product as “AB” rated; and (4) prelaunch press releases describing the drug as “generic Vascepa” and quoting Vascepa sales figures attributable to both the SH and CV indications.

The district court dismissed under Rule 12(b)(6). The Federal Circuit reversed in 2024, holding it was “at least plausible that a physician could read” the statements “as an instruction or encouragement to” infringe. The Supreme Court granted certiorari and reversed the Federal Circuit.

The Court’s Holding

In a unanimous opinion by Justice Ketanji Brown Jackson, the Court held that Amarin’s complaint failed the Twombly / Iqbal pleading standard for induced infringement under § 271(b) and should have been dismissed.

The central error in the Federal Circuit’s analysis was the framing of the inquiry: “The central question is whether Amarin plausibly alleged that Hikma actively encouraged infringing uses, not merely whether doctors could plausibly read the alleged statements as instructions to infringe.” In footnote 3, the Court explicitly rejected the recent Federal Circuit trend — singling out its own 2021 GlaxoSmithKline v. Teva decision — that had drifted toward asking how prescribers might read a label rather than what the defendant actively did.

Drawing on Grokster, Global-Tech, and the Court’s recent decision in Cox Communications v. Sony Music Entertainment, the opinion sharpens the “active steps” element of induced infringement. Inducement requires “affirmative” rather than passive steps, must involve “purposeful, culpable expression and conduct” that is “designed to stimulate others to commit” infringement, and cannot rest on “ordinary acts incident to product distribution.” At the same time, the Court rejected Hikma’s argument that inducement must be “express”: citing StreamCast’s “OpenNap” naming from Grokster, the Court reaffirmed that implicit encouragement can suffice — so long as the message is “clear” and “affirmative.”

Applying these standards, the Court walked through each category of Hikma’s statements and found that, individually and together, they did not plausibly allege active encouragement:

• The label’s retained clinical-study information and omission of the CV Limitation of Use. These have an “obvious alternative explanation” under Twombly: by statute, the generic label must be identical to the brand label except for the carved-out use, see 21 U.S.C. § 355(j)(2)(A)(v) and the “duty of sameness” recognized in PLIVA v. Mensing. The Court declined to “put generic manufacturers between a rock and a hard place by turning adherence to the law and industry standards into building blocks for illegal conduct.”
• The “generic Vascepa” / “generic equivalent” press-release language. Describing a generic by reference to its branded comparator is “normal industry practice,” citing Inwood Laboratories v. Ives.
• Omissions from the label and press releases. Under Twitter v. Taamneh, “mere omissions, inactions, or nonfeasance” cannot ground active inducement. Otherwise “ordinary merchants could become liable for any misuse of their goods and services, no matter how attenuated their relationship with the wrongdoer.”
• The patient information leaflet. Its cardiovascular-disease side-effect warning and its general off-label disclaimer are “implausibly roundabout ways to induce medical providers to infringe.” Treating warnings against a patented use as encouragement of it would erase the breathing room § 271(b) leaves for generic manufacturers.
• The website’s “hypertriglyceridemia” category and “AB” rating. Describing the drug’s therapeutic category as “hypertriglyceridemia” rather than “severe hypertriglyceridemia,” the Court analogized, is akin to calling a leukemia drug a “cancer drug” — a broad category, not an instruction to prescribe for a patented use. The “AB” rating, by its own definition, applies only under the labeling’s approved conditions, which exclude patented uses. The website itself clarified that Hikma’s generic was “indicated for fewer than all approved indications” of Vascepa.
• Sales figures in press releases. The “vaguest” of the alleged statements. They were directed to investors, not doctors, and Amarin’s theory required “myriad steps” of speculation about how providers would react. That chain was “possible” but not “plausible.”

Because Amarin pleaded only “more than a sheer possibility” — and not the plausible affirmative encouragement Iqbal requires — the Court reversed and remanded.

Key Takeaways

• The inquiry is about the defendant’s conduct, not how third parties might read it. The Court explicitly rejected the Federal Circuit’s recent drift toward asking whether physicians “could read” a label as encouragement, including a direct shot at GlaxoSmithKline v. Teva.
• Inducement does not have to be express. Implicit encouragement can suffice, but the message has to be “clear” and “affirmative” — not a contingent chain inferred from neutral statements.
• Mere omissions do not induce. Citing Twitter v. Taamneh, the Court held that what the label or a press release fails to say cannot be repackaged as active inducement.
• Compliance with the law and industry norms is an “obvious alternative explanation.” Following the statutory duty of sameness, using the term “generic equivalent,” and assigning an “AB” rating all flow from how the Hatch-Waxman scheme is built — they cannot be turned into evidence of active encouragement.
• Investor-directed press releases are weak inducement evidence. A plaintiff cannot bridge an inducement claim by stacking inferences about what a prescriber might do after reading a message aimed at investors.

Why It Matters

This is a significant win for the generic-drug industry and for the integrity of the Hatch-Waxman skinny-label mechanism. The Federal Circuit’s 2024 decision had let an inducement case proceed on the back of unremarkable, statutorily required, or industry-standard statements — the kind that essentially every skinny-label generic launch involves. If that ruling had stood, generic makers would have faced a strong incentive either to avoid section viii skinny-label launches when method-of-use patents covered popular indications, or to price years of motion-to-dismiss litigation into the cost of entry. Either response would have softened a core piece of the Hatch-Waxman bargain and dulled the cost savings generics deliver.

For branded pharmaceutical companies, the decision narrows but does not close the door on inducement claims against skinny-label generics. A plaintiff can still survive a motion to dismiss by pointing to affirmative conduct genuinely designed to stimulate infringing uses — explicit promotional language, targeted communications to prescribers, or implicit-but-clear cues of the kind Grokster’s “OpenNap” program supplied. What plaintiffs cannot do is rest the case on the background fact that physicians substitute generics for brand drugs, or on neutral disclosures that the law and industry practice require. Method-of-use patents covering new indications remain valuable; the inducement theory built around them just got narrower.

Two further practical effects are worth flagging. First, the Court’s explicit rejection of the Federal Circuit’s “physician could read it that way” framing — including the direct shot at GlaxoSmithKline v. Teva — will reshape how brand companies plead and litigate skinny-label cases going forward. Second, the Court’s invocation of Twitter v. Taamneh to bar omission-based inducement gives generic defendants a clean, recently decided Supreme Court hook at the motion-to-dismiss stage.